Instil Bio (NASDAQ:TIL) focuses on the development and commercialization of tumor-infiltrating lymphocyte (TIL) therapies for patients with cancer. Pioneering in the field of immuno-oncology, the company is harnessing the power of the body's immune system to target and destroy cancer cells. Instil Bio's main objective is to provide new, effective treatment options through its robust pipeline of TIL products, aiming to improve outcomes for patients facing various types of malignancies. As of my last update, Instil Bio is only traded on the NASDAQ under the ticker symbol TIL, concentrating its innovative efforts on progressing clinical trials and expanding its portfolio of TIL therapies to make a significant impact in oncology.